AN2 THERAPEUTICS INC (ANTX)
US0373261058 - Common Stock
ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q4 2023
ANTX stock results show that AN2 Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips AN2 Therapeutics (NASDAQ:ANTX) just reported results for the fourth quarter of ...
AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
Transitioning HBV cure programs into multiple late-stage combination studies with interim results throughout 2024 and 2025 informing Company's registrational...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AN2 Therapeutics, Inc. ("AN2" or the "Company") (NASDAQ: ANTX). Such investors...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AN2 Therapeutics, Inc. ("AN2" or the "Company") (NASDAQ: ANTX). Such investors...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AN2 Therapeutics, Inc. ("AN2" or the "Company") (NASDAQ: ANTX). Such investors...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AN2 Therapeutics, Inc. ("AN2" or the "Company") (NASDAQ: ANTX). Such investors...
AN2 Therapeutics stock falls as Leerink cuts on trial setback
AN2 Therapeutics (ANTX) shares dropped as Leerink Partners downgraded the company after it paused enrollments in a clinical trial. Read more here.
Oversold Conditions For AN2 Therapeutics (ANTX)
AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference
AN2 Therapeutics reports Q3 results (NASDAQ:ANTX)
AN2 Therapeutics reported a Q3 net loss of $16.7 million, compared to $11.3 million in the same period last year.
AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights
AN2 Therapeutics to Present at Upcoming Investor Conferences
AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease
AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023
AN2 Therapeutics director and 10% owner disposes stake in the company (NASDAQ:ANTX)
AN2 Therapeutics (ANTX) director and 10% owner Kabeer Aziz sold 104,773 company shares at $16.07 - $16.28 apiece, as per a recent SEC filing.
AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria
AN2 Therapeutics up 5%, RA Capital buys $16M stock (NASDAQ:ANTX)
AN2 Therapeutics (ANTX) stock price is up 4.5%, 10% owner, RA Capital bought ~1.78M shares of the company at $9 per share worth $16M on August 18, 2023.This brings his total share...
ANTX Makes Bullish Cross Above Critical Moving Average
AN2 Therapeutics prices $70.0 million stock offering (NASDAQ:ANTX)
AN2 Therapeutics (ANTX) on Tuesday priced an underwritten offering of 7.78 million shares of its common stock at a price of $9.00 per share.RA Capital Management, TCGX, Frazier...
AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock
AN2 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights
Brii Biosciences Provides Latest Clinical Development and Corporate Updates
Company extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri® in Greater China and Asia Pacific markets New data from...